Home / Health / High Court Upholds Controversial Puberty Blocker Trial in UK
High Court Upholds Controversial Puberty Blocker Trial in UK
3 Aug
Summary
- High Court rejected a challenge to a clinical trial on puberty blockers for teens.
- The PATHWAYS trial will investigate NHS support for gender incongruent youth.
- The judge found no grounds for the challenge, allowing the trial to proceed.
In a significant ruling on July 31, 2026, the UK's High Court dismissed a legal challenge seeking to halt the PATHWAYS trial, a clinical study on puberty blockers for teenagers with gender incongruence. Mr Justice Chamberlain stated that none of the challenge's grounds had a realistic prospect of success, allowing the trial to proceed.
The PATHWAYS trial, approved after an initial review in November 2025 and subsequent modifications, aims to determine how the NHS can better support children and young people experiencing gender incongruence. The trial was subject to a legal challenge brought by a campaign group and two individuals.
Following concerns raised by the MHRA in February 2026, King's College London proposed protocol modifications. These changes, reviewed and approved in June 2026, include strengthened safeguards like minimum entry ages (11 for females, 12 for males) and clearer discontinuation measures for safety and bone health.
This ruling comes amidst ongoing debate and a 2024 ban on puberty blockers for under-18s in the UK, following the Cass Review which cited "currently an unacceptable safety risk". The Health Research Authority welcomed the court's decision, emphasizing the robust safeguards in place for participants.
